USRE33495E - Stereoselective preparation of 3-substituted-4-anilino-piperidine compounds and derivatives - Google Patents

Stereoselective preparation of 3-substituted-4-anilino-piperidine compounds and derivatives Download PDF

Info

Publication number
USRE33495E
USRE33495E US07/413,427 US41342789A USRE33495E US RE33495 E USRE33495 E US RE33495E US 41342789 A US41342789 A US 41342789A US RE33495 E USRE33495 E US RE33495E
Authority
US
United States
Prior art keywords
lower alkyl
iaddend
iadd
alkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US07/413,427
Inventor
Linas V. Kudzma
H. Kenneth Spencer
Sherry A. Savernak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anaquest Inc
Original Assignee
BOC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/115,276 external-priority patent/US4849521A/en
Application filed by BOC Inc filed Critical BOC Inc
Priority to US07/413,427 priority Critical patent/USRE33495E/en
Application granted granted Critical
Publication of USRE33495E publication Critical patent/USRE33495E/en
Assigned to ANAQUEST, INC. A DE CORPORATION reassignment ANAQUEST, INC. A DE CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: BOC, INC., A CORPORATION OF DE
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Definitions

  • the present invention relates to a stereoselective tandem substitution and reduction reaction of .[.4-(cinalino) piperidine.]. .Iadd.4-anilino-piperidine .Iaddend.derivatives.
  • the resulting 3,4-cis compounds are useful intermediates leading to intravenous analgesics.
  • U.S. Pat. No. 4,584,303 discloses a method of preparing compounds of the following formula: ##STR1## wherein R 1 is .[.a lower alkyl, lower cyclic alkyl, lower alkyl lower cyclic alkyl, lower alkenyl, lower alkyl phenyl.]. .Iadd.hydrogen or methyl.Iaddend.; R 2 is phenyl or .[.aromatic heterocycle ring either of which may be.]. .Iadd.phenyl .Iaddend.substituted; and R 3 may be a variety of groups including .[.alkyl phenyl.]. .Iadd.phenyl alkyl.Iaddend.. With respect to the R 1 and NHR 2 substituents, it is desirable to obtain the more pharmacologically active cis isomer.
  • the invention is directed to a method of preparing a compound of the following formula: ##STR2## wherein R 1 is lower alkyl, lower .[.cylic.]. .Iadd.cyclic .Iaddend.alkyl, .[.lower alkyl.].
  • R 2 is a phenyl or aromatic heterocycle ring either of which may be substituted with one or more groups selected from the group consisting of lower alkoxy, lower alkyl, halogen, or combinations thereof; and R 3 can be a wide variety of groups, for example, selected from phenyl lower alkyl, thiazolyl lower alkyl, which can be substituted in the 4-position with a lower alkyl group, (4,5-dihydro-5-oxo-1H-tetrazol-1-yl) lower alkyl, which can be substituted in the 4-position with a lower alkyl, and substituted phenyl lower alkyl in which the substituents on the phenyl ring are selected from halogen, lower alkoxy, lower alkyl or combinations thereof
  • an aryl imine precursor is capable of being stereoselectively substituted in a single reactor without requiring intermediate separations or purifications.
  • Readily available starting materials are utilized and no special protection of the piperidine nitrogen is necessary.
  • Very high selectivity of the cis isomer typically 96%) can be achieved, resulting in an easier purification at an early stage of the overall synthetic route leading to the final product. Production of the nonrecyclable trans isomer is minimized.
  • R 1 is lower alkyl, lower cyclic alkyl, .[.lower alkyl.]. lower cyclic alkyl .Iadd.lower alkyl.Iaddend., lower alkenyl, or .Iadd.phenyl .Iaddend.lower alkyl .[.phenyl.].;
  • R 2 is a phenyl or aromatic heterocycle ring either of which may be substituted with one or more groups selected from the group consisting of lower alkoxy, lower alkyl, halogen, or combinations thereof;
  • R 3 is selected from a wide variety of groups, including phenyl lower alkyl, thiazolyl lower alkyl, which can be substituted in the 4-position with a lower alkyl group, (4,5-dihydro-5-oxo-1H-tetrazol-1-yl) lower alkyl, which can
  • lower alkyl, lower alkoxy, lower cyclic alkyl, or lower alkenyl are meant branched or unbranched chain groups with seven or less carbon atoms and preferably 5 or less carbons.
  • aromatic heterocycle ring is meant a fully unsaturated ring having 5 or 6 members including 0-3 nitrogen atoms and 0-2 oxygen or sulfur atoms.
  • halogen is meant to include fluoro, chloro, bromo, or iodo substituents.
  • R 1 groups examples include methyl, ethyl, cyclopropyl, cyclopropylmethyl, allyl and benzyl.
  • R 2 groups examples include phenyl, 2-fluorophenyl, 2-methylphenyl, 2-methoxyphenyl, pyrazolyl, or thienyl.
  • R 3 groups examples include phenyl ethyl, .Iadd.benzyl, .Iaddend.2-(4-ethyl-4-4,5-dihydro-5-oxo-1H-tetrazol-1-yl)ethyl, and 2-(4-methyl-thiazoyl)ethyl.
  • N-substituted-3-substituted-4-piperidone intermediate compound conventionally employed, for example, in the prior art synthetic route of U.S. Pat. No. 4,584,303.
  • This latter compound is difficult to make.
  • Applicants' above described reaction scheme begins with the intermediate compound N-substituted-4-piperidone, which is commercially available from Aldrich Chemical Co. (Milwaukee, Wis.) or Chemical Dynamics Corp. (So. Plainfield, N.J.) or else easily made by a Mannich condensation, as will be readily appreciated by those skilled in the art.
  • the latter piperidone compound is then reacted with a substituted or unsubstituted phenyl amine or aromatic heterocyclic amine to form the imine precursor .[.(III).]. .Iadd.(II) .Iaddend.above.
  • This reaction is suitably carried out in the presence of p-toluene sulfonic acid and refluxed while collecting water.
  • the imine precursor .[.(III).]. .Iadd.(II) .Iaddend. is then stirred at a low temperature with a non-nucleophilic base such as freshly prepared lithium diisopropyl amide in order to deprotonate the imine.
  • Non-nucleophilic bases include LDC (lithium dicyclohexylamide), LIC (lithium isopropylcyclohexylamide), LTP (tetramethylpiperamide) and LHS [lithium bis(trimethylsilyl)]amide.
  • substituting agents are iodides, bromides and chlorides. Tosylates and mesylates and other substituting agents known to those skilled in the art are also suitable.
  • the most preferred reducing agent is "Super-Hydride”.Iadd., i.e. lithium triethylborohydride, .Iaddend.because of its superior combination of cis selectivity and speed.
  • Other preferred hindered borohydride reducing agents include L-selectride (lithium tri-sec-butylborohydride, 1.0 molar in THF) and N ⁇ -Enantride (lithium hydride, a 9- ⁇ N-nopolbenzyl ether adduct, 0.5 molar in THF).
  • a cis:trans selectivity of greater than 90 percent and typically 96 percent is thereby obtainable.
  • Suitable reducing agents include Red-Al (sodium bis(2-methoxy-ethoxy)aluminum hydride, 3.4 molar in toluene, and LiAlH 4 . Typically, a selectivity of only about 60-70 percent cis:trans is obtained with the latter reducing agents. All of the above named reducing agents are commercially available from Aldrich Chemical Co. (Milwaukee, Wis.).
  • a major advantage of the above described synthetic route is that the reactions occur in a single vessel by the sequential introduction of the necessary reactants. Consequently, successive isolations and purifications are obviated, thereby greatly simplifying the overall route to a variety of therapeutic agents, notably of the fentanyl type, which are used in humans for inducing anesthesia or analgesia, for example .[.A-3331.]. .Iadd.cis-1[2-(4-ethyl-4-5-dihydro-5-oxy-1H-tetrazol-1-yl)ethyl]-3-methyl-4-[N-2(2-fluorophenyl methoxyacetamido] piperidine hydrochloride.Iaddend..
  • This example illustrates the preparation of .[.1-benzyl-3-(cis-methyl)-4-[N-(20fluorophenyl)amino]piperidine.]. .Iadd.1-benzyl-3-(cis-methyl)-4-(2-fluorophenyl) amino piperidine.Iaddend..
  • LDA was prepared under an atmosphere of argon by adding freshly distilled diisopropyl amine, 15 ml (107 mmol) dropwise to a cold (0° C.) solution of 55 mls of 1.6M n-butyllithium (88 mmol) in hexane in 60 mls of anhydrous THF. After 15 minutes at 0° C. the LDA solution was cooled to -78° C. in an isopropanol-dry ice slush bath. The solution of imine .[.1.]. (80.31 mmol) was added dropwise with stirring. The reaction was stirred at -78° C.
  • Example 2 In an analogous manner to the synthesis of Example 1, except using 1-iodopropane, benzyl bromide, and (bromomethyl)-cyclopropane, respectively as the substituting agent, the following compounds were prepared: ##STR10## .[.1-benzyl-3-[cis-(n-propyl)]-4-[N-(2-fluorophenyl)amino]-N piperidine.]. .Iadd.1-benzyl-3-[cis-(n-propyl)]-4-2-fluorophenyl)amino piperidine .Iaddend.oil at R.T.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention is directed to an improved stereoselective tandem substitution and reduction of an imine precursor to the cis form of .[.3-substituted-4-(phenylamino)piperidine.]. .Iadd.3-substituted-4-anilino piperidine .Iaddend.compounds or their substituted derivatives.

Description

BACKGROUND OF THE INVENTION
The present invention relates to a stereoselective tandem substitution and reduction reaction of .[.4-(cinalino) piperidine.]. .Iadd.4-anilino-piperidine .Iaddend.derivatives. The resulting 3,4-cis compounds are useful intermediates leading to intravenous analgesics.
U.S. Pat. No. 4,584,303 discloses a method of preparing compounds of the following formula: ##STR1## wherein R1 is .[.a lower alkyl, lower cyclic alkyl, lower alkyl lower cyclic alkyl, lower alkenyl, lower alkyl phenyl.]. .Iadd.hydrogen or methyl.Iaddend.; R2 is phenyl or .[.aromatic heterocycle ring either of which may be.]. .Iadd.phenyl .Iaddend.substituted; and R3 may be a variety of groups including .[.alkyl phenyl.]. .Iadd.phenyl alkyl.Iaddend.. With respect to the R1 and NHR2 substituents, it is desirable to obtain the more pharmacologically active cis isomer.
The method taught in U.S. Pat. No. .[.3,584,303.]. .Iadd.4,584,303 .Iaddend.for preparing compounds of .Iadd.the above .Iaddend.formula .[.(I).]. requires a multi-step synthetic route involving the preparation of cis isomers at an advanced stage of the synthetic route. Furthermore, a cis:trans ratio of not greater than 70:30 can be achieved.
J. Burke, Jr. et al., J. Med. Chem., Vol. 29, No. 6, pp 1087-1093 (1986), discloses a method to prepare piperidine derivatives, which method suffers the same disadvantages of the above-mentioned prior art method. Furthermore, the multi-step method of Burke et al. requires expensive starting materials and protection of the piperidine nitrogen.
The deprotonation of aliphatic imines followed by alkylation is generally known as, for example, shown by Collum et al., J. Am. Chem. Soc., Vol. 106, pp 4865-4869 (1984). The reduction of an imine is in itself also conventional.
SUMMARY OF THE INVENTION
The invention is directed to a method of preparing a compound of the following formula: ##STR2## wherein R1 is lower alkyl, lower .[.cylic.]. .Iadd.cyclic .Iaddend.alkyl, .[.lower alkyl.]. lower cyclic alkyl .Iadd.lower alkyl.Iaddend., lower alkenyl, or .Iadd.phenyl .Iaddend.lower alkyl .[.phenyl.].; R2 is a phenyl or aromatic heterocycle ring either of which may be substituted with one or more groups selected from the group consisting of lower alkoxy, lower alkyl, halogen, or combinations thereof; and R3 can be a wide variety of groups, for example, selected from phenyl lower alkyl, thiazolyl lower alkyl, which can be substituted in the 4-position with a lower alkyl group, (4,5-dihydro-5-oxo-1H-tetrazol-1-yl) lower alkyl, which can be substituted in the 4-position with a lower alkyl, and substituted phenyl lower alkyl in which the substituents on the phenyl ring are selected from halogen, lower alkoxy, lower alkyl or combinations thereof.
According to the method of the present invention, an aryl imine precursor is capable of being stereoselectively substituted in a single reactor without requiring intermediate separations or purifications. Readily available starting materials are utilized and no special protection of the piperidine nitrogen is necessary. Very high selectivity of the cis isomer (typically 96%) can be achieved, resulting in an easier purification at an early stage of the overall synthetic route leading to the final product. Production of the nonrecyclable trans isomer is minimized.
DETAILED DESCRIPTION OF THE INVENTION
Applicants have found an improved method for the efficient and economical preparation of compounds according to formula .[.(I).]. below: ##STR3## wherein R1 is lower alkyl, lower cyclic alkyl, .[.lower alkyl.]. lower cyclic alkyl .Iadd.lower alkyl.Iaddend., lower alkenyl, or .Iadd.phenyl .Iaddend.lower alkyl .[.phenyl.].; R2 is a phenyl or aromatic heterocycle ring either of which may be substituted with one or more groups selected from the group consisting of lower alkoxy, lower alkyl, halogen, or combinations thereof; and R3 is selected from a wide variety of groups, including phenyl lower alkyl, thiazolyl lower alkyl, which can be substituted in the 4-position with a lower alkyl group, (4,5-dihydro-5-oxo-1H-tetrazol-1-yl) lower alkyl, which can be substituted in the 4-position with a lower alkyl, and substituted phenyl lower alkyl in which the substituents on the phenyl ring are selected from halogen, lower alkoxy, lower alkyl or combinations thereof.
By the term lower alkyl, lower alkoxy, lower cyclic alkyl, or lower alkenyl are meant branched or unbranched chain groups with seven or less carbon atoms and preferably 5 or less carbons. By aromatic heterocycle ring is meant a fully unsaturated ring having 5 or 6 members including 0-3 nitrogen atoms and 0-2 oxygen or sulfur atoms. The term halogen is meant to include fluoro, chloro, bromo, or iodo substituents.
Examples of suitable R1 groups include methyl, ethyl, cyclopropyl, cyclopropylmethyl, allyl and benzyl.
Examples of suitable R2 groups include phenyl, 2-fluorophenyl, 2-methylphenyl, 2-methoxyphenyl, pyrazolyl, or thienyl.
Examples of suitable R3 groups include phenyl ethyl, .Iadd.benzyl, .Iaddend.2-(4-ethyl-4-4,5-dihydro-5-oxo-1H-tetrazol-1-yl)ethyl, and 2-(4-methyl-thiazoyl)ethyl.
The route to compounds of the .[.formula (I).]. .Iadd.invention .Iaddend.proceeds as follows: ##STR4## wherein R1, R2 and R3 are as defined above and R1 X is a reagent capable of adding the R1 group to the 3 position of the piperidine ring, for example, a lower alkyl iodide alkylating agent.
It is noted that the present invention does not involve the N-substituted-3-substituted-4-piperidone intermediate compound conventionally employed, for example, in the prior art synthetic route of U.S. Pat. No. 4,584,303. This latter compound is difficult to make. Instead, Applicants' above described reaction scheme begins with the intermediate compound N-substituted-4-piperidone, which is commercially available from Aldrich Chemical Co. (Milwaukee, Wis.) or Chemical Dynamics Corp. (So. Plainfield, N.J.) or else easily made by a Mannich condensation, as will be readily appreciated by those skilled in the art. The latter piperidone compound is then reacted with a substituted or unsubstituted phenyl amine or aromatic heterocyclic amine to form the imine precursor .[.(III).]. .Iadd.(II) .Iaddend.above. This reaction is suitably carried out in the presence of p-toluene sulfonic acid and refluxed while collecting water. The imine precursor .[.(III).]. .Iadd.(II) .Iaddend.is then stirred at a low temperature with a non-nucleophilic base such as freshly prepared lithium diisopropyl amide in order to deprotonate the imine. Other suitable non-nucleophilic bases include LDC (lithium dicyclohexylamide), LIC (lithium isopropylcyclohexylamide), LTP (tetramethylpiperamide) and LHS [lithium bis(trimethylsilyl)]amide.
By removal of the alpha (to the schiff base) proton, the following anion is generated: ##STR5##
Addition of a substituting agent R1 X such as the alkylating agent alkyl iodide results in the anion .[.IIIa.]. .Iadd.(IIa) .Iaddend.attaching the electrophile R1 X to form the following alkylated imine intermediate. ##STR6##
The most preferred substituting agents are iodides, bromides and chlorides. Tosylates and mesylates and other substituting agents known to those skilled in the art are also suitable.
Finally, without the necessity of isolating .[.(IIIb),.]. .Iadd.the alkylated imine compound (III) .Iaddend.a very selective reduction to the desired valuable intermediate (IV) above is carried out. This reduction is a steric approach control reaction wherein the least crowded side of the .[.intermediate (IIIb).]. .Iadd.alkylated imine compound (III) .Iaddend.is preferably .[.attached.]. .Iadd.attacked .Iaddend.by a relatively highly hindered reducing agent such as the hindered borohydride reducing agents.
The most preferred reducing agent is "Super-Hydride".Iadd., i.e. lithium triethylborohydride, .Iaddend.because of its superior combination of cis selectivity and speed. Other preferred hindered borohydride reducing agents include L-selectride (lithium tri-sec-butylborohydride, 1.0 molar in THF) and Nβ-Enantride (lithium hydride, a 9-ββN-nopolbenzyl ether adduct, 0.5 molar in THF). A cis:trans selectivity of greater than 90 percent and typically 96 percent is thereby obtainable. Other suitable reducing agents include Red-Al (sodium bis(2-methoxy-ethoxy)aluminum hydride, 3.4 molar in toluene, and LiAlH4. Typically, a selectivity of only about 60-70 percent cis:trans is obtained with the latter reducing agents. All of the above named reducing agents are commercially available from Aldrich Chemical Co. (Milwaukee, Wis.).
A major advantage of the above described synthetic route is that the reactions occur in a single vessel by the sequential introduction of the necessary reactants. Consequently, successive isolations and purifications are obviated, thereby greatly simplifying the overall route to a variety of therapeutic agents, notably of the fentanyl type, which are used in humans for inducing anesthesia or analgesia, for example .[.A-3331.]. .Iadd.cis-1[2-(4-ethyl-4-5-dihydro-5-oxy-1H-tetrazol-1-yl)ethyl]-3-methyl-4-[N-2(2-fluorophenyl methoxyacetamido] piperidine hydrochloride.Iaddend.. The remaining steps in the overall synthesis to such compounds are disclosed in detail in U.S. Pat. No. 4,584,303 to Huang et al., which hereby is incorporated by reference. Other compounds which may be prepared by a synthetic route within the scope of the present invention include β-hydroxyl-3-methylfentanyl and cis-3-methyl fantanyl (known in the chemical and pharmaceutical literature as F-7302 and R 26,800, respectively) which have demonstrated potent analgesic activity.
EXAMPLE 1
This example illustrates the preparation of .[.1-benzyl-3-(cis-methyl)-4-[N-(20fluorophenyl)amino]piperidine.]. .Iadd.1-benzyl-3-(cis-methyl)-4-(2-fluorophenyl) amino piperidine.Iaddend.. A solution of 1-benzyl-4-piperidone, 15.20 gms (80.31 mmol), 2-fluoroaniline, 9.02 gms (81.17 mmol) and p-toluenesulfonic acid monohydrate, 0.48 gms in 200 ml of toluene was refluxed overnight under argon collecting water in a Dean-Stark trap. After 18 hours the theoretical amount of water had separated and the trap was drained several times to distill off 100 mls of toluene. The reaction was cooled under argon and diluted with 40 mls anhydrous THF. The deep orange solution of crude imine .[.1.]. was used "as is" for next step. ##STR7##
LDA was prepared under an atmosphere of argon by adding freshly distilled diisopropyl amine, 15 ml (107 mmol) dropwise to a cold (0° C.) solution of 55 mls of 1.6M n-butyllithium (88 mmol) in hexane in 60 mls of anhydrous THF. After 15 minutes at 0° C. the LDA solution was cooled to -78° C. in an isopropanol-dry ice slush bath. The solution of imine .[.1.]. (80.31 mmol) was added dropwise with stirring. The reaction was stirred at -78° C. for 1 hour followed by rapid addition of methyl iodide, 12.9 gms (90.88 mmol). The reaction was stirred at -78° C. for 15 minutes followed by warming to room temperature. After 10 minutes at -78° C. a precipitate formed which redissolved as the reaction warmed up. After stirring at room temperature for 2 hours the reaction was cooled to 0° C. in an ice bath and 120 mls. 1.0M .[.Lithium triethlyborohydride.]. .Iadd.lithium triethylborohydride .Iaddend.in THF was added dropwise via syringe. The reaction was stirred overnight (16 hours) warming to room temperature. The reaction was then cooled back down to 0° C. and 50 mls of water was added slowly dropwise (exotherm and vigorous gas evolution). The quenched reaction mixture was concentrated to a pasty oil which was dissolved in 200 mls toluene and washed with 100 mls of water. The toluene layer was separated, dried over anhydrous sodium sulfate and concentrated to give a crude mixture of cis and trans diamine. Analytical LC showed the cis/trans diamine ratio to be 92.2:7.8. This crude oil was flash chromatographed on Silica 60, 230-444 mesh (444 gms) eluting with 1:10 EtOAc/Hex with 0.1% ammonium hydroxide added to give 9.74 gms pure cis diamine (40.6%) shown below and 1.57 gms cis and trans .[.diammine.]. .Iadd.diamine .Iaddend.mixture. Total isolated yield of cis and trans .[.diammine.]. .Iadd.diamine .Iaddend.was 47.2%. ##STR8##
M.P.: 55°-56° C.
NMR: 7.40(s,5H), 7.20-6.35(m,4H), 3.90(br s,1H), 3.40(br s,2H), 3.00-1.30(complex,8H), 0.95(d,3H)
EXAMPLE 2
In an analogous manner to the synthesis of Example 1, except using allyl bromide as the substituting agent, the compound .[.1-benzyl-3-(cis-allyl)-4-[N-(2-fluorophenyl)amino]piperidine.]. .Iadd.1-benzyl-3-(cis-allyl)-4-(2-fluorophenyl)amino piperidine .Iaddend.was prepared having the following formula: ##STR9## oil at room temperature
NMR: 7.30 (m,5H), 6.95(m,2H), 6.60(m,2H), 5.65(m,1H), 4.45(m,2H), 3.95(br 2,1H), 3.60(m,1H), 3.50 (ABq,2H), 2.60-1.65(complex,9H)
EXAMPLES 3-5
In an analogous manner to the synthesis of Example 1, except using 1-iodopropane, benzyl bromide, and (bromomethyl)-cyclopropane, respectively as the substituting agent, the following compounds were prepared: ##STR10## .[.1-benzyl-3-[cis-(n-propyl)]-4-[N-(2-fluorophenyl)amino]-N piperidine.]. .Iadd.1-benzyl-3-[cis-(n-propyl)]-4-2-fluorophenyl)amino piperidine .Iaddend.oil at R.T.
NMR: 7.40(s,5H), 7.40-6.50(m,4H), 3.95(br s, 1H), 3.60(m,1H), 3.50(ABq,2H), 2.60-0.30(complex,14H) ##STR11## .[.1-benzyl-3-(cis-benzyl)-4-[N-(2-fluorophenylamino)]piperidine.]. .Iadd.1-benzyl-3-(cis-benzyl)-4-(2-fluorophenyl)amino piperidine .Iaddend.oil at R.T.
NMR: 7.40-6.40(complex,14H), 4.05(m,1H), 3.50(br s,2H), 3.85-1.45(complex,10H). ##STR12## .[.1-benzyl-3-[cis-(cyclopropyl)methyl]-4-[N-(20fluorophenylamino)]piperidine.]. .Iadd.1-benzyl-3-[cis-(cyclopropyl)methyl]-4-(2-fluorophenyl)amino piperidine .Iaddend.oil at R.T.
NMR: 7.50-6.50(m,9H), 4.35(m,1H), 3.40(br s,2H) 3.35-0.80(complex,10H), 0.60-0.05(m,5H)
It will be understood that the embodiments described herein are merely exemplary and that a person skilled in the art may make variations and modifications without departing from the spirit and scope of the invention. All such modifications and variations are intended to be included within the scope of the invention as defined in the appended claims.

Claims (17)

We claim:
1. A method of preparing the cis isomer of a 4-anilino-3-R1 -piperidine, wherein R1 is lower alkyl, lower cyclic alkyl, .[.lower alkyl.]. lower cyclic alkyl .Iadd.lower alkyl.Iaddend., .Iadd.phenyl .Iaddend.lower alkyl .[.phenyl.]., or lower alkenyl, said method comprising:
(i) depronating a 4-imine piperidine with a non-nucleophilic base to form a deprotonated anion at the 3-position of the piperidine ring;
(ii) reacting said deprotonated anion with a substituting agent to introduce an R1 group in said 3-position; and
(iii) reducing the compound resulting from step (ii) to produce the cis isomer thereof, whereby a cis:trans selectivity of greater than about 90 percent is obtainable.
2. A method of preparing a .Iadd.cis .Iaddend.compound of the formula: ##STR13## wherein R1 is a lower alkyl, lower .[.cylic.]. .Iadd.cyclic .Iaddend.alkyl, .[.lower alkyl.]. lower cyclic alkyl .Iadd.lower alkyl.Iaddend., lower alkenyl or .Iadd.phenyl .Iaddend.lower alkyl .[.phenyl.].; R2 is a phenyl which may be substituted with one or more substituents selected from the group consisting of lower alkoxy, lower alkyl, halogen or combinations thereof, and R3 is selected from the group consisting of phenyl-lower-alkyl, thiazoyl lower alkyl which can be substituted in the 4-position with a lower alkyl group, (4,5-dihydro-4-oxo-1H-tetrazol-1-yl) lower alkyl which can be substituted in the 4-position with a lower alkyl, and substituted phenyl lower alkyl in which the substituents on the phenyl ring are selected from halogen, lower alkoxy, lower alkyl, or combinations thereof; said method comprising:
(i) deprotonating a compound of the following formula: ##STR14## with a non-nucleophilic base to form a deprotonated anion at the 3-position of the piperidine ring;
(ii) reacting said anion with a substituting agent to introduce said .[.Rgroup.]. .Iadd.R1 group .Iaddend.in said 3-position; and
(iii) reducing the compound resulting from step (ii) to produce the .Iadd.cis .Iaddend.compound .[.(1).]. above, .[.thereby obtaining the cis isomer thereof,.]. whereby a cis:trans selectivity of greater than about 90 percent is obtainable.
3. The method of claim 1 or 2, wherein said non-nucleophilic base is a lithium lower alkyl amide.
4. The method of claim 3, wherein said lithium lower alkyl amide is selected from the group consisting of lithium diisopropylamide, lithium dicyclohexylamide, lithium isopropylcyclohexylamide, lithium tetramethylpiperamide and lithium bis(trimethylsilyl)amide.
5. The method of claim 1 or 2 wherein said substituting agent is an alkylating agent.
6. The method of claim 1 or 2 wherein said deprotonating is carried out in a solvent comprising tetrahydrofuran.
7. The method of claim 5, wherein said alkylating agent is an iodide or tosylate.
8. The method of claim 7, wherein said iodidc is an alkyl iodide.
9. The method of claim 1 or 2, wherein said reducing is by means of a hindered borohydride reducing agent.
10. The method of claim 9, wherein said hindered borohydride reducing agent is selected from the group consisting of lithium triethylborohydride, lithium tri-sec-butylborohydride, .[.or.]. .Iadd.and .Iaddend.lithium hydride 9-ββN-nopolbenzylether adduct.
11. The method of claim 1 or 2, wherein the steps (i) through (iii) are carried out continuously without purification or isolation of intermediates.
12. The method of claim 11, wherein the said steps (i) through (iii) are continuously carried out in the same reactor means.
13. The method of claim 1 or 2, wherein said cis isomer is purified from minor amounts of the trans isomer.
14. A method for preparing a .Iadd.cis .Iaddend.compound of the formula: ##STR15## wherein R1 is a lower alkyl, lower .[.cylic.]. .Iadd.cyclic .Iaddend.alkyl, lower .[.alkyl lower cylic alkyl,.]. .Iadd.cyclic alkyl .Iaddend.lower alkyl, lower alkenyl, or .Iadd.phenyl .Iaddend.lower alkyl .[.phenyl.].; R2 is a phenyl, which may be substituted with one or more substituents selected from the group consisting of lower alkoxy, lower alkyl, halogen or combinations thereof, and R3 is selected from the group consisting of phenyl-lower-alkyl, thiazoyl lower alkyl which can be substituted in the 4-position with a lower alkyl group, (4,5-dihydro-4-oxo-1H-tetrazol-1-yl) lower alkyl which can be substituted in the 4-position with a lower alkyl, and substituted phenyl lower alkyl in which the substituents on the phenyl ring are selected from halogen, lower alkoxy, lower alkyl, halogen or combinations thereof; said method comprising:
(i) reacting H2 NR2 with a compound of the following formula: ##STR16## .Iadd.to form an imine compound of the formula ##STR17##.Iaddend. (ii) deprotonating the compound .[.of formula (2).]. with a non-nucleophilic base to form a deprotonated anion at the 3-position of the piperidine ring;
(iii) reacting said anion with a substituting agent to introduce an R1 group in said 3-position; and
(iv) reducing the compound of step .[.(ii).]. .Iadd.(iii) .Iaddend.to produce the .Iadd.cis .Iaddend.compound .[.(1).]. above, thereby obtaining the cis isomer thereof, whereby a cis:trans selectivity of greater than about 90 percent is obtainable.
15. The method of claim 14, wherein said substituting agent is an alkylating agent.
16. The method of claim 15, wherein said non-nucleophilic base is a lithium lower alkyl amide.
17. The method of claim 14 wherein said compound is reduced by introducing a hindered borohydride reducing agent.
US07/413,427 1987-11-02 1989-09-27 Stereoselective preparation of 3-substituted-4-anilino-piperidine compounds and derivatives Expired - Fee Related USRE33495E (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US07/413,427 USRE33495E (en) 1987-11-02 1989-09-27 Stereoselective preparation of 3-substituted-4-anilino-piperidine compounds and derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/115,276 US4849521A (en) 1987-11-02 1987-11-02 Stereoselective preparation of 3-substituted-4-piperidine compounds and derivatives
US07/413,427 USRE33495E (en) 1987-11-02 1989-09-27 Stereoselective preparation of 3-substituted-4-anilino-piperidine compounds and derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US07/115,276 Reissue US4849521A (en) 1987-11-02 1987-11-02 Stereoselective preparation of 3-substituted-4-piperidine compounds and derivatives

Publications (1)

Publication Number Publication Date
USRE33495E true USRE33495E (en) 1990-12-18

Family

ID=26813027

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/413,427 Expired - Fee Related USRE33495E (en) 1987-11-02 1989-09-27 Stereoselective preparation of 3-substituted-4-anilino-piperidine compounds and derivatives

Country Status (1)

Country Link
US (1) USRE33495E (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208329A (en) * 1990-10-09 1993-05-04 Merck & Co., Inc. 2-biphenyl carbapenem intermediates
US5425615A (en) * 1994-09-30 1995-06-20 All American Transit Parts Combination folding stair and platform wheelchair lift
US6531481B2 (en) 1998-03-10 2003-03-11 Research Triangle Institute Opiate compounds, methods of making and methods of use

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3161637A (en) * 1961-10-10 1964-12-15 Res Lab Dr C Janssen N V 1-(gamma-aroyl-propyl)-4-(nu-arylcarbonyl amino) piperidines and related compounds
US3164600A (en) * 1961-10-10 1965-01-05 Res Lab Dr C Janssen N V 1-aralkyl-4-(n-aryl-carbonyl amino)-piperidines and related compounds
US3907811A (en) * 1973-09-11 1975-09-23 Janssen Pharmaceutica Nv Stereoisomeric forms of 4-anilido-3-methyl-piperidine-1-carboxylates
US3907813A (en) * 1973-09-11 1975-09-23 Janssen Pharmaceutica Nv Stereoisomeric forms of 4-anilino-3-methyl piperidines
US3998834A (en) * 1975-03-14 1976-12-21 Janssen Pharmaceutica N.V. N-(4-piperidinyl)-n-phenylamides and -carbamates
US4196210A (en) * 1975-09-23 1980-04-01 Janssen Pharmaceutica N.V. N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides
EP0119558A1 (en) * 1983-03-14 1984-09-26 Hoechst-Roussel Pharmaceuticals Incorporated Stereoselective reduction of 2- or 3-substituted 4-piperidones with sodium borohydride
US4584303A (en) * 1984-04-09 1986-04-22 The Boc Group, Inc. N-aryl-N-(4-piperidinyl)amides and pharmaceutical compositions and method employing such compounds

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3161637A (en) * 1961-10-10 1964-12-15 Res Lab Dr C Janssen N V 1-(gamma-aroyl-propyl)-4-(nu-arylcarbonyl amino) piperidines and related compounds
US3164600A (en) * 1961-10-10 1965-01-05 Res Lab Dr C Janssen N V 1-aralkyl-4-(n-aryl-carbonyl amino)-piperidines and related compounds
US3907811A (en) * 1973-09-11 1975-09-23 Janssen Pharmaceutica Nv Stereoisomeric forms of 4-anilido-3-methyl-piperidine-1-carboxylates
US3907813A (en) * 1973-09-11 1975-09-23 Janssen Pharmaceutica Nv Stereoisomeric forms of 4-anilino-3-methyl piperidines
US3998834A (en) * 1975-03-14 1976-12-21 Janssen Pharmaceutica N.V. N-(4-piperidinyl)-n-phenylamides and -carbamates
US4196210A (en) * 1975-09-23 1980-04-01 Janssen Pharmaceutica N.V. N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides
EP0119558A1 (en) * 1983-03-14 1984-09-26 Hoechst-Roussel Pharmaceuticals Incorporated Stereoselective reduction of 2- or 3-substituted 4-piperidones with sodium borohydride
US4584303A (en) * 1984-04-09 1986-04-22 The Boc Group, Inc. N-aryl-N-(4-piperidinyl)amides and pharmaceutical compositions and method employing such compounds

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Drugs for the Future", vol. 9, No. 4, 1984, pp. 197-198 and 262-263.
D. B. Collum et al., "Substituent Effects on the Stereo-Chemistry, etc", 2/13/84, 4 pages, J. Am. Chem. Soc. 106, (4865-4869O.
D. B. Collum et al., Substituent Effects on the Stereo Chemistry, etc , 2/13/84, 4 pages, J. Am. Chem. Soc. 106, (4865 4869O. *
Drugs for the Future , vol. 9, No. 4, 1984, pp. 197 198 and 262 263. *
T. R. Burke et al., "Probes for Narcotic Receptor Mediated Phoenomena, etc.", J. Med. Chem., 1986, 29, 1087-1093 (7 pages).
T. R. Burke et al., Probes for Narcotic Receptor Mediated Phoenomena, etc. , J. Med. Chem., 1986, 29, 1087 1093 (7 pages). *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208329A (en) * 1990-10-09 1993-05-04 Merck & Co., Inc. 2-biphenyl carbapenem intermediates
US5425615A (en) * 1994-09-30 1995-06-20 All American Transit Parts Combination folding stair and platform wheelchair lift
US6531481B2 (en) 1998-03-10 2003-03-11 Research Triangle Institute Opiate compounds, methods of making and methods of use
US6552032B2 (en) 1998-03-10 2003-04-22 Research Triangle Institute Opiate compounds, methods of making and methods of use
US6593348B2 (en) 1998-03-10 2003-07-15 Research Triangle Institute Opiate compounds, methods of making and methods of use
US20040146518A1 (en) * 1998-03-10 2004-07-29 Research Triangle Institute Novel opiate compounds, methods of making and methods of use
US6900228B1 (en) 1998-03-10 2005-05-31 Research Triangle Institute Opiate compounds, methods of making and methods of use

Similar Documents

Publication Publication Date Title
EP0529702B1 (en) Dihydropyridine derivatives, their preparation and their use
US4581456A (en) Processes for preparing picenadol precursors and novel intermediates thereof
US4849521A (en) Stereoselective preparation of 3-substituted-4-piperidine compounds and derivatives
CA1120036A (en) 4-(naphthylmethyl)piperidine derivatives
USRE33495E (en) Stereoselective preparation of 3-substituted-4-anilino-piperidine compounds and derivatives
EP0315405B1 (en) 4-phenyl-4-(N-(2-fluorophenyl)amido) piperidine derivatives
SK10972000A3 (en) Method for producing (-)cis-3-hydroxy-1-methyl-4-(2,4,6- -trimethoxyphenyl)-piperidine
US4236009A (en) Method of preparing 4A-arylhexahydro-1H-2-pyrindines and 4A-aryloctahydroisoquinolines
US4500527A (en) Antihypertensive 4[(3-alkylamino-2-hydroxypropyl)-oxyiminomethyl phenyl]-1,4-dihydropyridines
US5013742A (en) 4-phenyl-4-N-(phenyl) amido piperidine derivatives and pharmaceutical compositions and method employing such compounds
US4839348A (en) 1,4-dihydropyridines
AU619238B2 (en) Stereoselective preparation of 3-substituted-4-(phenyl anilo) piperidine compounds and derivatives
US5145967A (en) Method for preparing 4-alkoxyalkyl-4-phenylaminopiperdines and derivatives thereof
EP1347960A1 (en) Process for preparing ( ) trans-4-p-fluorophenyl-3-hydroxymethyl-1
US4921864A (en) 4-Phenyl-4-(N-(phenyl)amido) piperidine derivatives and pharmaceutical compositions and method employing such compounds
US2856407A (en) Aminoacid esters of n-substituted 3 and 4-piperidinols
US4957929A (en) 4-phenyl-4-[N-(phenyl)amido]piperidine compounds and pharmaceutical compositions employing such compounds
US4098791A (en) Process for preparing 3-(cyanimino)-3-amino-propionitriles
US4663460A (en) Intermediates for picenadol
US4931558A (en) Processes for preparing intermediates of picenadol
WO2006074264A2 (en) Preparation of ketone amides
US4144245A (en) 4-Hydroxymethyl-2-pyrrolidinones
US4727149A (en) Preparation of nitriles of fused ring pyridine derivatives
US5021587A (en) Synthesis of N,3,4-trisubstituted-3-azoline-2-ones
US4277608A (en) Method of preparing 4a-arylhexahydro-1H-2-pyrindines and 4a-aryloctahydroisoquinolines

Legal Events

Date Code Title Description
AS Assignment

Owner name: ANAQUEST, INC. A DE CORPORATION, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:BOC, INC., A CORPORATION OF DE;REEL/FRAME:005881/0938

Effective date: 19911017

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees